Clinical Trial Update: Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy of a new formulation of rhNGF at 20 µg/ml with antioxidant in Neurotrophic Keratitis completed (results posted 2019-06-14)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratitis

Drugs mentioned

• rhNGF (recombinant human nerve growth factor) with new formulation and antioxidant (recombinant human nerve growth factor)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Neurotrophic Keratitis | Phase 2 | Status: COMPLETED | Results posted: 2019-06-14